EMEA-003599-PIP01-24 - paediatric investigation plan
trastuzumab-exatecan derivative antibody-drug conjugate
PIPHuman
Key facts
- Active Substance
- trastuzumab-exatecan derivative antibody-drug conjugate
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0270/2024
- PIP number
- EMEA-003599-PIP01-24
- Pharmaceutical form(s)
- All pharmaceutical forms
- Condition(s) / indication(s)
- Treatment of breast cancer
- Treatment of endometrial cancer
- Route(s) of administration
- All routes of administration
- Contact for public enquiries
BioNTech SE
E-mail: service@biontech.de
Tel: +49 (0) 6131 90840- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date